HK Stock Market Move | CSPC PHARMA (01093) gains nearly 3% in the morning session. SYS 6010 drug receives breakthrough therapy designation from the National Medical Products Administration.

CSPC PHARMA (01093) rose nearly 3% in the morning session, rising 2.66% to HK$4.65 as at the time of writing, with a trading volume of HK$21.9374 million. In recent news, CSPC PHARMA announced that its subsidiary, Giantstone Biopharma Co., Ltd., has developed SYS 6010 (Anti-human EGFR humanized monoclonal antibody - JS-1 conjugate injection), which has been granted breakthrough therapy designation by the China National Medical Products Administration. It is intended to be used as a monotherapy for EGFR mutation-positive late-stage non-small cell lung cancer (NSCLC) patients who have failed EGFR-TKI and platinum-containing chemotherapy. It is reported that the product is currently being developed for various solid tumors, and existing clinical data has confirmed that the efficacy of this product as a monotherapy in this indication is significantly better than standard treatment. The breakthrough therapy designation will help facilitate further communication with regulatory agencies and accelerate the development progress.